Jeffrey Bluestone Sells 5,000 Shares of Gilead Sciences (NASDAQ:GILD) Stock

Gilead Sciences, Inc. (NASDAQ:GILD) Director Jeffrey Bluestone sold 5,000 shares of Gilead Sciences stock in a transaction on Tuesday, January 20th. The stock was sold at an average price of $123.50, for a total transaction of $617,500.00. Following the transaction, the director owned 8,920 shares in the company, valued at approximately $1,101,620. This trade represents a 35.92% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink.

Jeffrey Bluestone also recently made the following trade(s):

• On Friday, November 28th, Jeffrey Bluestone sold 5,000 shares of Gilead Sciences stock. The stock was sold at an average price of $125.08, for a total transaction of $625,400.00.

Gilead Sciences Trading Up 4.0%

Shares of Gilead Sciences stock traded up $4.97 on Wednesday, reaching $129.11. 7,284,590 shares of the company’s stock were exchanged, compared to its average volume of 6,826,865. The company has a debt-to-equity ratio of 1.03, a quick ratio of 1.31 and a current ratio of 1.45. The company has a market capitalization of $160.18 billion, a P/E ratio of 20.02, a price-to-earnings-growth ratio of 0.66 and a beta of 0.33. The firm’s 50-day moving average is $123.53 and its two-hundred day moving average is $118.29. Gilead Sciences, Inc. has a 52 week low of $91.84 and a 52 week high of $129.39.

Gilead Sciences (NASDAQ:GILD) last posted its earnings results on Thursday, October 30th. The biopharmaceutical company reported $2.47 EPS for the quarter, topping the consensus estimate of $2.16 by $0.31. Gilead Sciences had a net margin of 27.88% and a return on equity of 51.86%. The company had revenue of $7.77 billion during the quarter, compared to the consensus estimate of $7.42 billion. During the same period in the previous year, the firm posted $2.02 earnings per share. The firm’s revenue for the quarter was up 3.0% on a year-over-year basis. Gilead Sciences has set its FY 2025 guidance at 8.050-8.250 EPS. Sell-side analysts predict that Gilead Sciences, Inc. will post 7.95 EPS for the current fiscal year.

Gilead Sciences Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Tuesday, December 30th. Shareholders of record on Monday, December 15th were paid a $0.79 dividend. The ex-dividend date was Monday, December 15th. This represents a $3.16 annualized dividend and a yield of 2.4%. Gilead Sciences’s dividend payout ratio is currently 48.99%.

Institutional Trading of Gilead Sciences

Institutional investors have recently made changes to their positions in the business. Brighton Jones LLC lifted its stake in Gilead Sciences by 20.6% in the fourth quarter. Brighton Jones LLC now owns 14,359 shares of the biopharmaceutical company’s stock worth $1,326,000 after purchasing an additional 2,450 shares during the last quarter. Bison Wealth LLC purchased a new position in shares of Gilead Sciences in the 4th quarter worth approximately $215,000. Sivia Capital Partners LLC increased its position in Gilead Sciences by 16.8% during the 2nd quarter. Sivia Capital Partners LLC now owns 4,182 shares of the biopharmaceutical company’s stock valued at $464,000 after buying an additional 602 shares in the last quarter. Silver Oak Securities Incorporated acquired a new position in shares of Gilead Sciences during the second quarter valued at about $415,000. Finally, Foster Group Inc. acquired a new position in Gilead Sciences during the 2nd quarter valued at approximately $207,000. Hedge funds and other institutional investors own 83.67% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts have recently issued reports on GILD shares. Weiss Ratings reaffirmed a “buy (b)” rating on shares of Gilead Sciences in a report on Wednesday, October 8th. The Goldman Sachs Group upped their price target on shares of Gilead Sciences from $110.00 to $115.00 and gave the company a “neutral” rating in a report on Thursday, January 8th. Rothschild & Co Redburn lifted their price target on Gilead Sciences from $153.00 to $159.00 and gave the company a “buy” rating in a research report on Tuesday. Truist Financial started coverage on shares of Gilead Sciences in a report on Monday, November 24th. They issued a “buy” rating and a $140.00 price objective on the stock. Finally, JPMorgan Chase & Co. raised their price target on Gilead Sciences from $145.00 to $150.00 and gave the company an “overweight” rating in a report on Friday, October 31st. One investment analyst has rated the stock with a Strong Buy rating, twenty-three have given a Buy rating and three have given a Hold rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $133.52.

About Gilead Sciences

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.